Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 11/20 | 0.92 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.92 |
| ▸ | PDE4A | P27815 | 8/20 | 0.92 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.92 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.92 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.92 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.92 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11661797 | 0.99 | ADORA2B (0.89) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL21381249 | 0.99 | ADORA2B (0.89) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL6233166 | 0.96 | ADORA2B (1.00) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL27395394 | 0.96 | ADORA2B (1.00) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL4423680 | 0.90 | ADORA2B (1.00) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL9432924 | 0.84 | ADORA2B (0.71) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| 1-Methylxanthine SCHEMBL17748264 | 0.84 | ADORA2B (0.89) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL5039468 | 0.84 | ADORA2B (0.74) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL31081359 | 0.84 | ADORA2B (0.74) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL8679545 | 0.84 | PDE4A (0.70) | ADORA2BADORA2APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009131948-A2 | HIGH-THROUGHPUT CELL-BASED CFTR ASSAY | INSTITUTE FOR ONEWORLD HEALTH (US) | 2009-10-29 | — | — | WO | claimed |
| US-11225481-B2 | Xanthine derivative inhibitors of BET proteins | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-01-18 | — | — | US | disclosed |
| US-20190292186-A1 | XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-09-26 | — | — | US | disclosed |
| EP-2721030-A1 | NOVEL PHTHALAZINONE-PYRROLOPYRIMIDINECARBOXAMIDE DERIVATIVES | Takeda GmbH (DE) | 2014-04-23 | — | — | EP | disclosed |
| EP-2721036-A1 | NOVEL 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO[4,3-C]ISOQUINOLINE COMPOUNDS | Takeda GmbH (DE) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012171900-A1 | NOVEL PHTHALAZINONE-PYRROLOPYRIMIDINECARBOXAMIDE DERIVATIVES | NYCOMED GMBH (DE) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012171903-A1 | NOVEL 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO[4,3-C]ISOQUINOLINE COMPOUNDS | NYCOMED GMBH (DE) | 2012-12-20 | — | — | WO | disclosed |
| WO-2011061398-A1 | BIOLOGICAL REGENERATE | TAMPEREEN YLIOPISTO (FI) | 2011-05-26 | — | — | WO | disclosed |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| EP-1751274-A1 | METHOD FOR PRODUCING PLURIPOTENT CELLS FROM MONOCYTESMETHOD FOR PRODUCING PLURIPOTENT CELLS FROM MONOCYTES | Peters, Hinrich (DE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005118779-A1 | METHOD FOR PRODUCING PLURIPOTENT CELLS FROM MONOCYTES | UNIV GOETTINGEN GEORG AUGUST (DE) | 2005-12-15 | — | — | WO | disclosed |
| US-5470579-A | Xanthines, optionally incorporated in liposomes, for promoting skin or hair pigmentation | LVMH, RECHERCHE (FR) | 1995-11-28 | — | — | US | disclosed |
| EP-0535038-A4 | MAMMALIAN ADIPOGENIC FACTORS | — | 1993-12-29 | — | — | EP | disclosed |
| EP-0535038-A1 | MAMMALIAN ADIPOGENIC FACTORS | W. ALTON JONES CELL SCIENCE CENTER (US) | 1993-04-07 | — | — | EP | disclosed |
| WO-1991018924-A1 | MAMMALIAN ADIPOGENIC FACTORS | W. ALTON JONES CELL SCIENCE CENTER (US) | 1991-12-12 | — | — | WO | disclosed |
| EP-0308460-A1 | A COMPOSITION FOR THE TOPICAL TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION. | PHARMACIA AB (SE) | 1989-03-29 | — | — | EP | disclosed |
| WO-1988007380-A1 | A COMPOSITION FOR THE TOPICAL TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION | PHARMACIA AB (SE) | 1988-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292186-A1 | XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS | BET1, BRD4, BRD3 | ADORA2B 3323/4885ADORA2A 3171/4885PDE4A 1873/4885 |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | XDH, GPR84, GPR88 | ADORA2B 111/4885ADORA2A 17/4885PDE4A 315/4885 |
| US-11225481-B2 | Xanthine derivative inhibitors of BET proteins | BET1, BRD4, BRD3 | ADORA2B 3323/4885ADORA2A 3171/4885PDE4A 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.